SAB Biotherapeutics shareholders elect directors, approve equity plan amendment, ratify auditor at 2024 annual meeting

SAB Biotherapeutics, Inc.

Shareholders elected Samuel J. Reich, Christine Hamilton, and Eddie J. Sullivan as Class III directors for three-year terms.
Approved amendment to 2021 Omnibus Equity Incentive Plan, increasing share reserve by 3.9M to 5.5M shares.
Ratified EisnerAmper LLP as independent registered public accounting firm for FY 2024.
Voting results: For director elections, votes ranged from 4.89M to 5.15M with ~1.3M broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.